GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipigon Pharmaceuticals AB (STU:9RP) » Definitions » Buyback Yield %

Lipigon Pharmaceuticals AB (STU:9RP) Buyback Yield % : -29.81 (As of Apr. 27, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Lipigon Pharmaceuticals AB Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Lipigon Pharmaceuticals AB's current buyback yield was -29.81%.


Lipigon Pharmaceuticals AB Buyback Yield % Historical Data

The historical data trend for Lipigon Pharmaceuticals AB's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipigon Pharmaceuticals AB Buyback Yield % Chart

Lipigon Pharmaceuticals AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial - - -74.36 -126.35 -78.05

Lipigon Pharmaceuticals AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.15 -79.40 -65.14 -12.55 -12.87

Competitive Comparison of Lipigon Pharmaceuticals AB's Buyback Yield %

For the Biotechnology subindustry, Lipigon Pharmaceuticals AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipigon Pharmaceuticals AB's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipigon Pharmaceuticals AB's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Lipigon Pharmaceuticals AB's Buyback Yield % falls into.


;
;

Lipigon Pharmaceuticals AB Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Lipigon Pharmaceuticals AB's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 3.868) / 4.9557424
=-78.05%

Lipigon Pharmaceuticals AB's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0.429) / 1.9431361
=-22.08%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Lipigon Pharmaceuticals AB Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Lipigon Pharmaceuticals AB's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipigon Pharmaceuticals AB Business Description

Traded in Other Exchanges
Address
Tvistevagen 48 C, Umea, SWE, 90736
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.

Lipigon Pharmaceuticals AB Headlines

No Headlines